Previous Article | Next Article 
Journal of Clinical Microbiology, August 2009, p. 2458-2464, Vol. 47, No. 8
0095-1137/09/$08.00+0 doi:10.1128/JCM.01863-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Performance of Human Papillomavirus DNA and mRNA Testing Strategies for Women with and without Cervical Neoplasia 
Ameli Tropé,1*,
Katrine Sjøborg,2,
Anne Eskild,1,3,4
Kate Cuschieri,5
Tormod Eriksen,6
Steinar Thoresen,6
Martin Steinbakk,7
Vigdis Laurak,7
Christine M. Jonassen,7
Unni Westerhagen,8
Morten B. Jacobsen,4,9 and
Agnes Kathrine Lie8,10
Department of Obstetrics and Gynaecology, Akershus University Hospital, Lørenskog, Norway,1 Department of Obstetrics and Gynaecology, Oestfold Hospital Trust, Fredrikstad, Norway,2 Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway,3 Faculty of Medicine, University of Oslo, Oslo, Norway,4 Specialist Virology Center, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom,5 Institute of Population-Based Cancer Research, Oslo, Norway,6 Department of Medical Microbiology, Akershus University Hospital, Lørenskog, Norway,7 Department of Pathology, Akershus University Hospital, Lørenskog, Norway,8 Department of Medicine, Oestfold Hospital Trust, Fredrikstad, Norway,9 Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway,10
Received 26 September 2008/ Returned for modification 24 November 2008/ Accepted 28 May 2009
In the present study we investigated the cross-sectional positivity for DNA and E6/E7 mRNA from high-risk human papillomavirus (HPV) types in 643 women with high-grade cervical neoplasia (135 cases of cervical intraepithelial neoplasia grade 2 [CIN2], 495 cases of CIN3/adenocarcinoma in situ [ACIS], and 13 cases of invasive carcinoma) and in 736 women with normal cytology by using the Amplicor and PreTect HPV-Proofer assays. In addition, genotyping was performed using Linear Array for women with normal cytology and a positive HPV test and in all women with histologically confirmed CIN2+. In women with normal cytology, 8.3% (61/736) were Amplicor positive and 3.3% (24/736) were PreTect HPV-Proofer positive (P < 0.001). Concordant results between the Amplicor and PreTect HPV-Proofer tests were present in 90.3% (665/736). In women with CIN2+ lesions 96.4% (620/643) were positive by Amplicor, 98.4% (633/643) by linear array, and 64.1% (412/643) by PreTect HPV-Proofer. Concordant results for the three HPV assays were present in 63.8%. The genotype profile detected by linear array and PreTect HPV-Proofer showed substantial agreement for HPV types 16, 18, 33, and 45. HPV type 16 and/or 18 was detected in 58.8% (378/643) of the women with high-grade neoplasia. Detection of E6/E7 mRNA by PreTect HPV-Proofer increased with severity of the cervical lesion. Detection of HPV DNA, however, was not associated with histology grade. In conclusion, the detection of HPV varied according to the assay used, and the concordance between the tests was poor. Our results indicate that mRNA testing may be a biomarker for progression of cervical neoplasia, but the optimal genotype mix remains to be determined.
* Corresponding author. Mailing address: Department of Obstetrics and Gynecology, Akershus University Hospital, Mailbox 24, 1478 Lørenskog, Norway. Phone: (47) 90655041. Fax: (47) 22935426. E-mail: ameli.trope{at}me.com
Published ahead of print on 17 June 2009.
Ameli Trope and Katrine Sjøborg contributed equally to this work.
Journal of Clinical Microbiology, August 2009, p. 2458-2464, Vol. 47, No. 8
0095-1137/09/$08.00+0 doi:10.1128/JCM.01863-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»